Outcomes and management of patients with mantle cell lymphoma after progression on brexucabtagene autoleucel therapy-Reference-Cited by-同舟云学术

Outcomes and management of patients with mantle cell lymphoma after progression on brexucabtagene autoleucel therapy

Published:2020-11-05 Issue:2 Volume:192 Page:
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:Br J Haematol

Author:

Jain Preetesh¹^ORCID,Nastoupil Loretta¹,Westin Jason¹,Lee Hun Ju¹,Navsaria Lucy¹,Steiner Raphael E.¹,Ahmed Sairah¹,Moghrabi Omar¹,Oriabure Onyeka¹,Chen Wendy¹,Badillo Maria¹,Flowers Christopher R.¹,Wang Michael L.¹

Affiliation:

1. Department of Lymphoma and Myeloma The University of Texas MD Anderson Cancer Center Houston TX USA

Publisher

Wiley

Subject

Hematology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/bjh.17197

Reference9 articles.

1. KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma

2. High‐risk mantle cell lymphoma: definition, current challenges, and management;Jain P.;J. Clin. Oncol.,2019

3. Genomic profiles and clinical outcomes of de novo blastoid/pleomorphic MCL are distinct from those of transformed MCL

4. TP53 mutations identify younger mantle cell lymphoma patients who do not benefit from intensive chemoimmunotherapy

5. Complex karyotype in patients with mantle cell lymphoma predicts inferior survival and poor response to intensive induction therapy

Cited by 35 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Chimeric antigen receptor T-cell therapy for aggressive B-cell lymphomas;Frontiers in Oncology;2024-07-01

2. CAR-T-Cell-Based Cancer Immunotherapies: Potentials, Limitations, and Future Prospects;Journal of Clinical Medicine;2024-05-29

3. Particle-Based Artificial Antigen-Presenting Cell Systems for T Cell Activation in Adoptive T Cell Therapy;ACS Nano;2024-03-14

4. Targeting Other Promising Cell Surface Receptors;Precision Cancer Therapies vol 2 ‐ Immunologic Approaches for the Treatment of Lymphoid Malignancies ‐ From Concept to Practice;2024-02-21

5. The HSP90-MYC-CDK9 network drives therapeutic resistance in mantle cell lymphoma;Experimental Hematology & Oncology;2024-02-07